VivoSeq
Other

Hepatoblastoma

8

Pipeline Programs↗

1

Active Trials↗

6

Companies Involved↗

Hepatoblastoma is an early-stage landscape with 8 programs across 6 companies. The most active players are Eastern Cooperative Oncology Group, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc., Pfizer. 7 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

34/100

Pipeline Velocity

0/100

Mech. Concentration

17/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

Eastern Cooperative Oncology Group

2 programs

Phase 3M

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

1 program

Phase 3Pfizer logo

Pfizer

1 program

Phase 3G

Gynecologic Oncology Group

1 program

Phase 3P

Prism Pharmaceuticals

1 program

Phase 3E

Eureka Therapeutics Inc.

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

2

clinical trials

Recruiting1 · 50%
Completed1 · 50%

Clinical Trials

Trial Activity

An Open-Label, Dose Escalation, Phase I/II Clinical Trial of ET140203 T Cells in Pediatric Subjects With Relapsed/Refractory Hepatoblastoma (HB), Hepatocellular Neoplasm-Not Otherwise Specified (HCN-NOS), or Hepatocellular Carcinoma (HCC)
Recruiting·EEureka Therapeutics Inc.·Preclinical·NCT04634357·12 enrolled
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Completed·National Cancer Institute (NCI)·Phase 3·NCT00980460·236 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)